Welcome back to the micro-cap trenches, where preferred equity is a weapon, debt amendments are a seasonal sport, and selling your AI subsidiary is the only way to make payroll. We flagged 35 alerts this week, but the real story lies in a fascinating GPU divestiture, some frantic capital structure engineering, and the classic reverse-split-and-dilute two-step. Let's look at the filings that matter.
The Great GPU Handoff
If you want to understand the lifecycle of an AI hardware bet, look no further than the deal between Duos Technologies Group (DUOT) and Axe Compute (AGPU). Duos has entirely given up on owning heavy hardware, selling its 100% stake in its GPUaaS subsidiary to Axe. The transaction offloads a cluster of 2,304 GPUs and forces Axe to swallow $87.8 million in subsidiary debt. Duos is owed a deferred purchase price, but the contract features an acceleration clause if Axe secures financing against the hardware—meaning Duos traded a revenue engine for credit risk.
Since the October 5 filing, the market has picked a clear winner. Axe Compute is taking a victory lap, preparing to ring the Nasdaq opening bell on October 12 while aggressively pitching its "capital-light" cloud marketplace narrative—an ironic spin for a company that just absorbed nearly $90 million in debt for bare-metal servers. Duos, meanwhile, caught a "Sell" downgrade from Wall Street Zen on October 10 and is lingering near its one-year lows. Relieving your balance sheet of heavy debt is nice, but Wall Street rarely rewards you for selling the most valuable thing you own.
The "Dividend" That Dilutes
Jaguar Health (JAGX) filed an 8-K admitting severe liquidity stress, actively delaying debt and royalty payments from October 2026 to January 2027. To keep the lights on, they also authorized a new class of Series R Convertible Preferred Stock that carries a brutal 5:1 conversion ratio. For common shareholders, this spells guaranteed, massive dilution when the conversion hits in November.
Naturally, retail traders misread the room completely. Because Jaguar distributed the preferred shares as a "special dividend," traders ignored the catastrophic conversion math and pumped the stock 36% on October 6, temporarily sending it above $6. The reality distortion field didn't last long, and the stock is already bleeding back into the mid-$4s. If you ever needed proof that the micro-cap biotech market doesn't read the footnotes, here it is.
Kicking the Covenant Can
FTC Solar (FTCI) filed its Third Amendment and Limited Waiver to its credit agreement. When a company hits its third amendment within a year just to delay a trivial $5 million debt repayment and beg for relief on revenue and EBITDA covenants, the underlying business is officially running on fumes. They managed to push their financial tests to 2027, buying time they almost certainly cannot afford.
The market reaction has been a collective yawn, which is the most dangerous response a micro-cap can get. Shares are drifting sideways below $2, pre-market volume is essentially non-existent, and analysts are modeling for the floor, with Financhill projecting a drop to $1.08. Survival is a necessary condition for a business, but it is not an investment thesis.
Cleaning House Before the Merger
Jasper Therapeutics (JSPR) held a special meeting to approve a reverse split of up to 1-for-35 and balloon its authorized share count from 490 million to 675 million. This is standard procedure for a company fighting to hold its Nasdaq listing, but the subsequent filings revealed the actual strategy.
On October 7, Jasper launched a cash tender offer to buy back 12.3 million outstanding warrants at $0.324 each, spending $4 million to wipe out the dilution overhang. Two days later, they filed a proxy to convert preferred stock from their Kira Pharmaceuticals acquisition into voting common stock. Jasper is frantically sanitizing its capital structure. The exact reverse split ratio is still pending, but the financial engineering here is aggressive, deliberate, and entirely focused on making the cap table presentable for institutional buyers.
What to Watch
Watch Jaguar Health in November when those Series R preferred shares actually convert and the dilution math becomes a harsh reality for the retail crowd. Also keep an eye on Axe Compute's cash burn; assuming $87.8 million in debt for a single GPU cluster is a heavy lift, and the clock is ticking to see if they can monetize that compute power fast enough to service the interest.